New Haven, CT, United States of America

Matthew Welsch

USPTO Granted Patents = 12 

Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 2020-2025

Loading Chart...
12 patents (USPTO):

Title: The Innovative Contributions of Matthew Welsch

Introduction

Matthew Welsch is a prominent inventor based in New Haven, Connecticut, known for his significant contributions to the field of pharmaceuticals. With a total of 12 patents to his name, Welsch has made strides in developing innovative compounds that target critical interactions in various diseases.

Latest Patents

Among his latest patents is a groundbreaking work on inhibitors of the menin-MLL interaction. This patent discloses heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. It also describes specific inhibitors of this interaction and pharmaceutical compositions that include these compounds. The methods of using these menin-MLL inhibitors are disclosed for the treatment of autoimmune diseases, heteroimmune diseases, and cancers, including lymphoma and leukemia. Another notable patent involves CD16a binding agents, which provide compounds and methods useful for treating various conditions, including cancer.

Career Highlights

Matthew Welsch has worked with notable companies in the pharmaceutical industry, including Biomea Fusion, Inc. and Vyera Pharmaceuticals, LLC. His work in these organizations has contributed to the advancement of therapeutic agents aimed at treating complex diseases.

Collaborations

Welsch has collaborated with esteemed colleagues such as Thomas Butler and Jim Palmer, further enhancing the impact of his innovative work in the field.

Conclusion

Matthew Welsch's contributions to pharmaceutical innovations through his patents and collaborations highlight his role as a key inventor in the industry. His work continues to pave the way for new treatments and therapies that address critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…